Zura Bio bets on dual IL-17 and BAFF inhibition across three immune-mediated disease
Explore how Zura Bio’s expanded tibulizumab Phase 2 program could change treatment development in HS and systemic sclerosis.
Pharma & Biotech
Pharma & Biotech
Does sonelokimab finally justify MoonLake’s best-in-class hidradenitis suppurativa claim?
Sonelokimab delivered deeper one-year hidradenitis suppurativa responses, but MoonLake must convert cross-trial advantages into regulatory approval and commercial differentiation.
Pharma & Biotech
Why Incyte’s povorcitinib 54-week results matter for hidradenitis suppurativa treatment
Incyte's povorcitinib reaches 71.4% HiSCR50 at 54 weeks in HS. Analysis of what the STOP-HS data mean for the JAK1 class and the treatment landscape.
Pharma & Biotech
Can Incyte’s 54-week povorcitinib data redefine the oral treatment landscape in hidradenitis suppurativa?
Incyte presents 54-week STOP-HS phase 3 data for povorcitinib at AAD 2026. Analyst review of durability, safety, and what the dataset means for the NDA.
Pharma & Biotech
Novartis expands Cosentyx label to adolescents with hidradenitis suppurativa
FDA approves Novartis Cosentyx for adolescent hidradenitis suppurativa. Discover what this decision means for biologic treatment strategies.